Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Safety and Tolerability of OLX10212 in Patients With Neovascular Age-Related Macular Degeneration

NCT05643118 is registered in ClinicalTrials.gov with Olix Pharmaceuticals, Inc. as lead sponsor.

NCT NCT05643118
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05643118 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Safety and Tolerability of OLX10212 in Patients With Neovascular Age-Related Macular Degeneration
Lead sponsor
Olix Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
January 4, 2023
Completion date
November 10, 2025
Enrollment
21 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration